Zacks Research Issues Negative Outlook for Sanofi Earnings

Sanofi (NASDAQ:SNY) – Stock analysts at Zacks Research lowered their Q1 2026 earnings per share (EPS) estimates for Sanofi in a report issued on Wednesday, February 19th. Zacks Research analyst K. Shah now forecasts that the company will post earnings of $1.05 per share for the quarter, down from their prior estimate of $1.06. The consensus estimate for Sanofi’s current full-year earnings is $4.36 per share. Zacks Research also issued estimates for Sanofi’s Q4 2026 earnings at $1.19 EPS, FY2026 earnings at $4.75 EPS and FY2027 earnings at $5.16 EPS.

A number of other research analysts have also commented on SNY. Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. StockNews.com lowered shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. Two investment analysts have rated the stock with a hold rating, one has given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $60.00.

Sanofi Price Performance

NASDAQ SNY opened at $54.46 on Friday. Sanofi has a 12 month low of $45.22 and a 12 month high of $58.97. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14. The firm has a market capitalization of $138.21 billion, a PE ratio of 21.87, a P/E/G ratio of 1.00 and a beta of 0.57. The company’s 50 day simple moving average is $50.95 and its 200 day simple moving average is $52.52.

Sanofi (NASDAQ:SNY) last released its quarterly earnings results on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in SNY. Synergy Asset Management LLC acquired a new position in Sanofi in the fourth quarter worth approximately $25,000. McClarren Financial Advisors Inc. grew its position in Sanofi by 952.6% in the fourth quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock worth $28,000 after buying an additional 543 shares during the last quarter. Lee Danner & Bass Inc. acquired a new position in Sanofi in the fourth quarter worth approximately $31,000. Bessemer Group Inc. grew its position in Sanofi by 59.8% in the fourth quarter. Bessemer Group Inc. now owns 647 shares of the company’s stock worth $32,000 after buying an additional 242 shares during the last quarter. Finally, Concord Wealth Partners grew its position in Sanofi by 157.8% in the third quarter. Concord Wealth Partners now owns 593 shares of the company’s stock worth $34,000 after buying an additional 363 shares during the last quarter. Institutional investors and hedge funds own 14.04% of the company’s stock.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.